Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna Inc, the biotech pioneering messenger RNA (mRNA) therapeutics and vaccines, said it has struck a deal to buy Japan-based OriCiro Genomics for US$85 million to boost its manufacturing capabilities.  "With this acquisition, we obtain best-in-class tools for cell-free synthesis and amplification of plasmid DNA, a key building block in mRNA manufacturing," said Stéphane Bancel, the CEO of Moderna, in a statement.

Moderna to buy Japan-based OriCiro Genomics for US$85M

The small Tokyo-based company's tools will help the pharma giant's messenger RNA manufacturing process.

Moderna Bolsters Its Vaccine Pipeline With $85 Million Deal for Biotech Firm OriCiro

Moderna Inc on Wednesday agreed to buy Japan-based OriCiro Genomics for $85 million to boost the U.S. drugmaker's messenger RNA (mRNA) manufacturing capabilities.

Moderna snaps up Japan's OriCiro Genomics in mRNA manufacturing push

OriCiro's synthetic biology and enzyme technologies will support Moderna's expanding portfolio of therapeutics and vaccines Acquisition will bolster Moderna's suite of platform technologies CAMBRIDGE, MA and TOKYO, JAPAN / ACCESSWIRE / January 4, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and OriCiro Genomics K.K., a pioneer in cell-free DNA synthesis and amplification technologies, today announced they have entered into a definitive agreement through which Moderna will acquire OriCiro for $85 million.

Moderna to Acquire OriCiro Genomics

CAMBRIDGE, MA / ACCESSWIRE / January 3, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that CEO Stéphane Bancel will present an update on the Company and its pipeline of mRNA development programs at the 41st annual J.P. Morgan Healthcare Conference on Monday, January 9th at 5:15 p.m.

Moderna to Provide Business and Pipeline Updates at the 2023 J.P. Morgan Healthcare Conference

AbbVie

Abbott Labs

Alnylam Pharmaceuticals

Amgen

argenx

AstraZeneca

Baxter

Bayer AG

BeiGene

Biogen

Bristol-Myers

United States Brent Oil Fund LP

BioNTech SE

CSL Ltd

Invesco DB Oil Fund

Daiichi Sankyo Co Ltd

Gilead Sciences

Genmab - ADR

Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 2X Shares

iShares U.S. Oil & Gas Exploration & Production ETF

Incyte

Johnson & Johnson

Eli Lilly

Merck

Novo Nordisk

Novartis

VanEck Vectors Oil Services ETF

iPath Pure Beta Crude Oil ETN

Pfizer

Invesco Dynamic Oil & Gas Services ETF

Reckitt Benckiser Group PLC

Regeneron Pharmaceuticals

Roche Holding AG

Royalty Pharma

Seagen

Takeda Pharmaceutical

ProShares Ultra Bloomberg Crude Oil

United States Oil Fund LP

Vertex Pharmaceuticals

SPDR S&P Oil & Gas Exploration & Production ETF

Medical and energy companies, including oil stocks, lead the list of the 100 best stocks in 2022. The post 100 Best Stocks Of 2022: Oil Stocks And Medicals Shine appeared first on Investor's Business Daily.

100 Best Stocks Of 2022: Oil Stocks And Medicals Shine

Tesla

Accenture Plc

Arista Networks

Broadcom

Carrier Global

Charter Communications

Dow Inc

Estee Lauder

Edwards Lifesciences

Fidelity National Information

Fortinet

Hilton Worldwide Holdings

IQVIA Hlds

ServiceNow

Otis Worldwide

PayPal

Zoetis

In the worst year for stocks since the Great Recession, several big names are headed for their worst year on record with just one trading day left in 2022.

Tesla is not alone: 18 (and a half) other big stocks are headed for their worst year on record

Catalyst Pharmaceuticals

The biotechnology space can be a difficult area to generate profits. Drugs take years to develop and often fail FDA approval.

Biotech: 3 Profitable Bios Worth Owning

Moderna Inc (NASDAQ: MRNA) has tanked nearly 15% in recent days but a Jefferies analyst dubs it one of his best ideas for 2023. Moderna stock could climb another 50% Earlier in December, the biotech company said its candidate vaccine for skin cancer showed encouraging results in a Phase II study (read more).

Jefferies analyst reveals his top two biotech stocks for 2023

NVIDIA

The stock market held up relatively well Tuesday, except for technology stocks, which fell hard as the 10-year Treasury yield spiked again. The post Stock Market Gets More Jittery As Bond Yields Jump Again; Sellers Hit Tesla, Moderna, Nvidia Hard appeared first on Investor's Business Daily.

Stock Market Gets More Jittery As Bond Yields Jump Again; Sellers Hit Tesla, Moderna, Nvidia Hard

It's been an otherwise poor year for this biotech on the stock market.

This Stock Just Soared by 20%: Should You Buy Now?

Moderna has agreed to invest in a Covid vaccine research and development and build a new vaccine manufacturing facility in the UK. “The deal is also a major boost for UK health research and will see the UK Health Security Agency (UKHSA) working with Moderna to ensure early vaccine development” said the government.

Moderna agrees 10-year vaccine manufacturing deal with UK

Axsome Therapeutics

Revenue prospects look promising for both of these biotech companies.

Better Buy: Moderna vs Axsome

U.S. biotech Moderna's planned vaccine manufacturing centre in Britain will create more than 150 new jobs in the country, the UK government said on Thursday.

Moderna's vaccine facility in Britain to create over 150 new jobs

Facility to enable access to domestically manufactured mRNA respiratory vaccines, pending regulatory assessment and licensure The ten-year strategic partnership is expected to provide the UK public with response capabilities to ensure future preparedness in light of the COVID-19 pandemic Moderna is expanding its presence in the UK through investments in R&D activities and capabilities CAMBRIDGE, MA / ACCESSWIRE / December 21, 2022 / Moderna, Inc . (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the finalization of a strategic partnership with the UK government to establish a state-of-the-art mRNA research, development, and manufacturing facility in the UK.

Moderna Finalizes Strategic Partnership with UK Government

Sanofi

With economic worries unsettling investors, it is not surprising that leading advisors, and contributors to MoneyShow.com, are looking to the pharmaceutical sector – Here's a look at seven global favorites, focused on such areas as obesity and diabetes to new applications for mRNA-based vaccines.

7 Healthy Buys Among Global Drug Makers

Merck and Moderna recently announced positive results from a trial involving their personalized cancer vaccine.

Could This Opportunity Make Moderna a Hot Buy Again?

Newly created role will have responsibility for commercial efforts in Europe, Middle East and Canada CAMBRIDGE, MA / ACCESSWIRE / December 20, 2022 / Moderna, Inc . (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the appointment of Chantal Friebertshäuser as Senior Vice President, Commercial, Europe, Middle East and Canada effective January 1, 2023.

Chantal Friebertshäuser Joins Moderna as Senior Vice President, Commercial

News for Moderna Stock (MRNA)